Clinical trial NCT05183555: Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis
Official title: Early Feasibility Study of Somatostatin Receptors PET Imaging (68Ga-DOTATOC PET/CT) for the Diagnosis of Infective Endocarditis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infective Endocarditis
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-01-10
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single-center, early feasibility clinical trial (RIPH1 type) using a radiopharmaceutical (drug) off-label.

This study is based on the evaluation of an off-label radiopharmaceutical, 68Ga-DOTATOC in PET/CT, to detect infective endocarditis. The marketing authorization of 68Ga-DOTATOC is for the neuroendocrine tumors assessment (NET). Currently, a clinical study using 68Ga-DOTATOC PET/CT to detect myocarditis in the inflammatory phase is conducted by a team of the CHRU of Nancy Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.
Primary purpose: DIAGNOSTIC

Brief summary: Study hypothesis: 68Ga-DOTATOC PET/CT could detect cardiac foci of infective endocarditis regardless of the type of valve (native or prosthetic) and also extracardiac localizations related to this pathology (infection responsible, peripheral emboli, ...). This study is a proof of concept with low population

Detailed description: The incidence of infective endocarditis (IE) in France is estimated to be around 30 cases per million inhabitants in studies conducted in Western countries and is significantly increased in patients with a valve prosthesis and even more so in cases of a history of endocarditis. The morbi-mortality is significant and the hospital mortality rate is 20%.

The diagnosis of IE remains difficult and according to the modified Duke criteria, the diagnostic sensitivity is 80%.

Currently, the diagnosis of IE is often determined according to the 2015 ESC criteria and the sensitivity increases from 57% to 84% regarding IE on prosthetic valves.

The 18F-FDG PET/CT examination is of major interest in the diagnosis of AR on prosthetic valves with a detection sensitivity of between 70 and 90% (with an accuracy of 70 to 80%). Concerning native valves, the sensitivity of PET/CT remains below 50%.

Indeed, a "physiological" myocardial fixation in 18F-FDG PET/CT compromises the interpretation of PET exam, so it is important to start a hypoglycemic-hyperlipidic diet the day before the 18F-FDG PET/CT, followed by a 12-hour fasting period.

For several years, a radiopharmaceutical, 68Ga-DOTATOC (68Ga-edotreotide) has been used in PET/CT for the diagnosis and follow-up of neuroendocrine tumours (NETs). 68Ga-DOTATOC binds mainly with high affinity to somatostatin receptor subtype 2 (SSTR2) but also to somatostatin receptor subtype 5 (SSTR5).

Activated monocytes, macrophages, and lymphocytes express somatostatin receptors , thus detection of SSTR2 receptors expressed by inflammatory cells could help for the diagnosis of infective endocarditis.

PET/CT with 68Ga-DOTATOC could thus detect inflammatory cells at infectious sites. This radiopharmaceutical has already shown an ability to identify a myocardial inflammation (inflammatory phase myocarditis and cardiac sarcoidosis).

In current study conducted by our teams (NCT03347760 on ClinicalTrials.gov), early results showed the capacity of the 68Ga-DOTATOC to detect efficiently myocarditis, including myocarditis induced by RNA anti-COVID vaccinations.

In vitro, the 18FDG uptake by inflammatory cells is more important than the 68Ga-DOTATOC uptake, but the contrast between infection focus and healthy tissue should be better since 68Ga-DOTATOC does not cause any physiological myocardial uptake. The 68Ga-DOTATOC does not required any special metabolic preparation or prolonged fasting often poorly supported by patients.

Eligibility criteria: Inclusion Criteria:

* Adult who has received full information about the organisation of the research and has signed informed consent adult
* Participant hospitalised for definite AE according to modified Duke criteria (Li), on native or prosthetic valve, referred for 18F-FDG PET/CT from Cardiology and Infectious Diseases departments

Exclusion Criteria:

* Person with a history of hypersensitivity from previous use of 68Ga-DOTATOC
* Unable to perform a 68Ga-DOTATOC PET scan (agitated, confused patient...).
* Inability to schedule 68Ga-DOTATOC PET/CT the day after 18F-FDG PET/CT.
* Person with severe renal impairment (GFR \<30 ml/min/1.73 m2)
* Participant treated with a somatostatin analogue.
* Participant with Cushing's syndrome
* Pregnant, potentially pregnant or breastfeeding women
* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
* Person of full age who is unable to give consent
* Person deprived of liberty by a judicial or administrative decision
* Person subject to psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1

Primary outcomes:
measure: Detectability of infective endocarditis by 68Ga-DOTATOC PET/CT
timeFrame: one year
Secondary outcomes:
measure: To quantify the infective foci uptake of 68Ga-DOTATOC
timeFrame: one year
measure: 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT results comparison
timeFrame: one year
measure: 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT results comparison of cardiac step
timeFrame: one year
Other outcomes:
Locations:
city: Vandoeuvre les Nancy cedex
country: France
facility: CHRU de NANCY
Study officials:
References: